XenoPort soars off upbeat preliminary results from Phase I studies of its potential MS treatment

Shares of XenoPort (XNPT +18%) soar today after the company released positive preliminary results late yesterday from two Phase I studies of XP23829.

Based on the favorable results, XNPT intends to continue to advance development of the drug as a potential treatment for patients with relapsing-remitting multiple sclerosis and/or psoriasis.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs